Kringle Pharma,Inc.
Develops regenerative HGF medicines for rare and intractable neurological diseases.
4884 | T
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- Japan
- Address:
- 茨木市彩都あさぎ七丁目７番１５号彩都バイオインキュベータ２０７号
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Kringle Pharma, Inc. is a late clinical-stage biopharmaceutical company focused on the research and development of regenerative medicines for intractable diseases. Originating as a university spin-off, the company's core strength is its proprietary platform for manufacturing pharmaceutical-grade recombinant human Hepatocyte Growth Factor (HGF). HGF is an endogenous protein with protective, regenerative, and tissue-repairing functions. Kringle Pharma is advancing its HGF drug candidates through clinical trials for several conditions, including rare and neurological diseases such as spinal cord injury and Amyotrophic Lateral Sclerosis (ALS).
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Kringle Pharma,Inc. and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-07-16 09:00 |
Prospectus
有価証券届出書（組込方式）
|
Japanese | 364.6 KB | |
| 2025-05-12 08:41 |
Regulatory News Service
確認書
|
Japanese | 8.2 KB | |
| 2025-05-12 08:40 |
Interim Report
半期報告書－第24期(2024/10/01－2025/09/30)
|
Japanese | 181.3 KB | |
| 2024-12-23 06:32 |
Regulatory News Service
臨時報告書
|
Japanese | 24.0 KB | |
| 2024-12-23 06:31 |
Regulatory News Service
確認書
|
Japanese | 8.2 KB | |
| 2024-12-23 06:30 |
Annual Report
有価証券報告書－第23期(2023/10/01－2024/09/30)
|
Japanese | 2.2 MB | |
| 2024-12-23 06:30 |
Regulatory News Service
内部統制報告書－第23期(2023/10/01－2024/09/30)
|
Japanese | 21.7 KB | |
| 2024-08-26 03:25 |
Regulatory News Service
臨時報告書
|
Japanese | 22.4 KB | |
| 2024-05-13 08:40 |
Quarterly Report
四半期報告書－第23期第2四半期(2024/01/01－2024/03/31)
|
Japanese | 179.6 KB | |
| 2024-05-13 08:40 |
Regulatory News Service
確認書
|
Japanese | 8.2 KB | |
| 2024-02-09 07:41 |
Regulatory News Service
確認書
|
Japanese | 8.2 KB | |
| 2024-02-09 07:40 |
Quarterly Report
四半期報告書－第23期第1四半期(2023/10/01－2023/12/31)
|
Japanese | 139.3 KB | |
| 2023-12-25 08:24 |
Regulatory News Service
臨時報告書
|
Japanese | 22.3 KB | |
| 2023-12-25 08:23 |
Regulatory News Service
確認書
|
Japanese | 8.2 KB | |
| 2023-12-25 08:22 |
Regulatory News Service
内部統制報告書－第22期(2022/10/01－2023/09/30)
|
Japanese | 21.6 KB |
Automate Your Workflow. Get a real-time feed of all Kringle Pharma,Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Kringle Pharma,Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
/other/Diamyd_Medical_AB_publ-logo.png){kind=logo}
